Palisade Bio (NASDAQ:PALI) Director Robert Jr. Baltera Buys 20,000 Shares

Palisade Bio, Inc. (NASDAQ:PALI) Director Robert Jr. Baltera purchased 20,000 shares of the business’s stock in a transaction on Wednesday, July 8th. The stock was purchased at an average price of $1.99 per share, with a total value of $39,800.00. Following the purchase, the director owned 436,904 shares of the company’s stock, valued at approximately $869,438.96. The trade was a 4.80% increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available through this link.

Robert Jr. Baltera also recently made the following trade(s):

• On Thursday, July 9th, Robert Jr. Baltera acquired 25,000 shares of Palisade Bio stock. The shares were purchased at an average price of $1.96 per share, for a total transaction of $49,000.00.
• On Tuesday, July 7th, Robert Jr. Baltera bought 30,000 shares of Palisade Bio stock. The stock was purchased at an average cost of $2.03 per share, for a total transaction of $60,900.00.
• On Monday, July 6th, Robert Jr. Baltera bought 20,000 shares of Palisade Bio stock. The stock was purchased at an average price of $2.05 per share, with a total value of $41,000.00.
• On Thursday, July 2nd, Robert Jr. Baltera purchased 10,000 shares of Palisade Bio stock. The shares were acquired at an average cost of $1.98 per share, with a total value of $19,800.00.
• On Wednesday, July 1st, Robert Jr. Baltera acquired 20,000 shares of Palisade Bio stock. The shares were bought at an average price of $1.98 per share, with a total value of $39,600.00.

Palisade Bio Stock Down 0.5%

Shares of Palisade Bio stock traded down $0.01 during trading on Friday, reaching $1.96. The company’s stock had a trading volume of 3,452,719 shares, compared to its average volume of 4,494,371. The firm has a market cap of $340.22 million, a PE ratio of -1.94 and a beta of 1.50. Palisade Bio, Inc. has a 52 week low of $0.53 and a 52 week high of $2.85. The business’s 50-day moving average price is $1.92 and its 200-day moving average price is $1.92.

Palisade Bio (NASDAQ:PALI) last released its earnings results on Tuesday, May 12th. The company reported ($0.05) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.04) by ($0.01). Equities analysts predict that Palisade Bio, Inc. will post -0.25 earnings per share for the current year.

Institutional Trading of Palisade Bio

A number of hedge funds have recently added to or reduced their stakes in PALI. Commodore Capital LP bought a new position in shares of Palisade Bio in the 4th quarter valued at $26,896,000. Perceptive Advisors LLC acquired a new stake in shares of Palisade Bio during the 4th quarter valued at $28,318,000. Artia Global Partners LP bought a new stake in Palisade Bio during the 4th quarter worth $4,682,000. BIT Capital GmbH bought a new stake in Palisade Bio during the 4th quarter worth $717,000. Finally, Creek Drive Management Group LLC acquired a new position in Palisade Bio in the 4th quarter worth about $723,000. Institutional investors and hedge funds own 11.79% of the company’s stock.

Analyst Upgrades and Downgrades

PALI has been the topic of several recent analyst reports. LADENBURG THALM/SH SH upgraded Palisade Bio to a “strong-buy” rating in a research note on Thursday, June 25th. Oppenheimer set a $7.00 price objective on Palisade Bio in a research report on Tuesday, June 30th. Wolfe Research initiated coverage on Palisade Bio in a research note on Thursday, April 9th. They issued an “outperform” rating and a $7.00 price objective on the stock. HC Wainwright reiterated a “buy” rating and issued a $2.00 target price on shares of Palisade Bio in a research report on Tuesday, June 30th. Finally, Weiss Ratings raised Palisade Bio from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Monday, June 29th. Two analysts have rated the stock with a Strong Buy rating, six have assigned a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Buy” and an average target price of $8.83.

About Palisade Bio

Palisade Bio, Inc is a clinical?stage biotechnology company focused on pioneering localized immunotherapies for the treatment of cancer and inflammatory diseases. The company leverages a proprietary prodrug platform designed to activate therapeutic agents selectively within the tumor microenvironment or sites of inflammation. Its core strategy centers on stimulating the innate immune system via toll?like receptor 9 (TLR9) agonism to drive targeted immune responses while minimizing systemic exposure and toxicity.

The company’s lead product candidate, PDS0108, is an intratumoral TLR9 agonist prodrug currently in Phase 1/2 clinical trials for patients with advanced solid tumors.